StockData

Integra LifeSciences vs Stevanato Group S.p.A.

IART and STVN side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IART and STVN compare

Stevanato Group S.p.A. grew revenue faster over the last twelve months (7.4% versus 0.84% for Integra LifeSciences).

Stevanato Group S.p.A. keeps more of each dollar of sales as profit, with a net margin of 11.8% compared with 0.79% at Integra LifeSciences.

Integra LifeSciences scores higher on the StockData Score (9 against 8 for Stevanato Group S.p.A.), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIARTSTVN
Size and price
Market cap$1.1B–
Share price$13.98$15.53
Change, 1 year16.1%−31.5%
Change, 5 years−78.4%−30.6%
Beta (5Y)1.871.87
Employees3,7006,010
StockData Score
Total score9 (better)8
Valuation score3 (better)0
Growth score22
Performance score34 (better)
Health score12 (better)
Dividend score00
Valuation
P/E82.2×–
P/S0.7×–
P/B1.0×–
EV/EBITDA10.7×–
P/FCF12.7×–
FCF yield7.9%–
Fair value$14.79–
Margin of safety5.5%–
Growth
Revenue growth (TTM)0.84%7.4% (better)
Revenue growth, 5Y average3.6%12.4% (better)
Net income growth (TTM)–18.7%
EPS growth (TTM)–18.6%
EPS growth, 5Y average–9.1%
Profitability
Gross margin52.4% (better)29.0%
Operating margin4.4%16.8% (better)
Net margin0.79%11.8% (better)
FCF margin5.2% (better)1.9%
Return on equity1.2%9.7% (better)
Return on invested capital5.6%11.0% (better)
Financial health
Interest coverage0.8×8.8× (better)
Current ratio3.62 (better)1.76
Altman Z-score1.28–
Piotroski F-score56 (better)
Dividends and buybacks
Payout ratio–10.5%
Shareholder yield0.00%–
Ownership
Held by institutions94.4%15.0%
Held by insiders3.4%83.9%
Insider net buying, 12 months$0$39.4K (better)
Short interest, % of float10.5%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.